Urologix software gets US FDA approval:
This article was originally published in Clinica
Urologix has received US FDA approval for its Cruise II enhancement for the Targis Cruise Control urological microwave catheter software. The new version incorporates a unique dual sensor feedback system providing automated safety controls and improved ease of use. The system achieves and sustains therapeutic temperatures within the prostate for an optimal treatment by utilising urethral and rectal temperatures, said the Minneapolis, Minnesota-based company.
You may also be interested in...
GNC hires Josh Burris as chief US officer; Clasado BioSciences adds Bellchambers as commercial director; and Barentz plans expansion with Cinven investment.
The House passage of a Democratic bill authorizing the federal government to negotiate drug prices in Medicare has sharpened the debate over how prices feed innovation, but the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Pink Sheet's table highlights the key provisions of HR 3 and other pending pricing legislation.